Table 2. Negative PCR results, cardiac conditions, seronegativation; negative parasitological tests after treatment with benznidazole and adverse events observed during the treatment.

Author	Treatment scheme of benznidazole	PCR results (%)	Cardiac conditions (%)	Serological parameters (%)	Parasitological parameters negative results (%)	Adverse effects
Alvarez et al.6	5 mg/kg/day, divided into two daily doses every 5 days, for a total of 60 days	94.0	-	-	-	Dermatitis (35.0%); gastrointestinal intolerance (25.0%); increased liver enzymes (20.0%); loss of appetite (5.0%); insomnia (5.0%). No serious adverse effects.
Andrade et al. 12	5 mg/kg/day/60 days	-	Maintained: 62.9	Unchanged: 69.2 Regressive: 23.1 Progressive: 7.7	-	-
Andrade et al. 13	5 mg/kg every 8 hours/60 days	-	Maintained: 76.2 Worsening: 19.0	Unchanged: 80.0 Regressive: 10.0 Progressive: 10.0		-
Antunes et al. 20	No dose information. BNZ for 50-60 days; BNZ > 60 days.	BNZ ≤60 days: 77.8 BNZ >60: 66.7	Maintained: 100.0	-	-	Allergic reactions (19.5%)
Braga et al.21	10 mg/Kg/day/ 30 or 60 days	< 1 to 36 T. cruzi/ml (means 6.45 ± 9.28)	-	-	-	-
Coura et al.22	5 mg/kg/twice daily/ 30 days	-	Maintained: 100.0	Unchanged: 100.0	98.2	Rash, peripheral neuropathy gastrointestinal disorders. The adverse effects were discrete or moderate.
Fabbro et al. 23	5 mg/kg/day/ 30 days with half of the dose in the first week.	-	Worsening: 3.7	Unchanged: 44,4 Regressive: 33,3 Progressive: 22,2	100.0	Maculopapular erythema (12.5%); pruritus and edema (3.7%). These patients had to stop the medication because of intolerance.
Fernández et al. 11	2.5-5.5 mg/Kg/ 60 days	100.0	-	-	-	Dermatitis, pruritus, oral mucositis, dysgeusia, paresthesia in lower limb, hypereosinophilia.
Lana et al.14	5-10 mg/kg/day for 40-60 consecutive days	14.8	Worsening: 4.6	Unchanged: 100.0	92.9	Anorexia, muscle pain, exanthema. One case of severe adverse effects was documented.
Laucella et al. 24	5 mg/kg/day/30 days	-	-	Unchanged: 81.5 Regressive: 13.9 Progressive: 4.6	-	-
Levi et al.15	5 mg/kg/day to 8 mg/kg/day/60 days	-	-	-	63.4	Vesicular rash, peripheral neuropathy and psychiatric manifestations, leading to discontinuation of treatment in 41.5% of the patients.
Molina et al.25	150 mg twice daily/ 60 days	61.5	-	-	-	Severe cutaneous reactions (6.4%) leading to discontinuation of treatment.
Morillo et al.26	300 mg per day with a variable duration of therapy (between 40 to 80 days)	At the end of the treatment: 66.2; 2 years: 55.4; 5 years or more: 46.7	Worsening at 2 years: 36.7; Worsening at 5 years or more: 38.2	-	-	Cutaneous rash, gastrointestinal symptoms, and nervous system disorders leading to discontinuation of treatment in 23.9% of the patients.
Morillo et al.27	20 0mg daily/ 60 days	BNZ+POS: 30 days: 88.9 60; days: 92.3; 360 days: 96.0 BNZ: 30 days: 89.7; 60 days: 89.3; 360 days: 96.0	-	-	-	Severe adverse events (7.0%): cutaneous rash, nervous system disorders and gastrointestinal signs and symptoms.
Oliveira et al.16	5 mg/kg twice daily/ 60 days	76.2	There was worsening of the heart rate.	-	-	-
Pérez-Antón et al.19	5 mg/kg/day/ 60 days	52.6	-	-	-	-
Perez- Mazliah et al. 17	Allopurinol: 600 mg/day/ 90 days followed by 30 days of BNZ (5 mg/kg/day)	-	-	Regressive: 73.0	-	Mild dermatitis (26.7%), moderate dermatitis (26.7%). Treatment discontinuation was required in two cases (13%): one during treatment with allopurinol and one during treatment with BNZ.
Pinazo et al.28	5 mg/kg/day/ 60 days	-	-	-	-	Gastrointestinal symptoms (76.0%); skin symptoms (74.0%), neurological/ musculoskeletal symptoms (74.0%), pruritus (70.0), fever (15.0%). Treatment was discontinued in 11 patients, 7 among them due to severe adverse effects.
Pinazo et al.29	5 mg/kg/day/ 60 days	75.0	-	-	-	-
Torrico et al. 30	5 mg/kg twice daily/ 60 days	97.0	-	Unchanged: 87.0 Regressive: 9.0 Inconclusive: 4.0	-	Severe adverse events: 4.0%
Vallejo et al. 33	5 mg/kg twice daily/ 60 days	100.0	-	-	-	Maculopapular rash, facial rash, fever, rash. Three discontinued therapy owing to adverse reactions.
Viotti et al.31	5 mg/kg/day/30 days	-	Worsening: 5.0	Regressive: 15.0	-	-
Viotti et al.32	5 mg/kg/day/30 days	-	Maintained: 100.0	Regressive: 40.0	-	-